Dear All: Oh, no! Hot on the heels of the excellent talk at GAMRIC by Karen Bush in which the importance of relebactam as one

Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in

Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity for organizations to sign a

Dear All, Recently posted, six concepts were approved for FY 2027 funding at the September 2025 meeting of NIAID’s Division of Microbiology and Infectious Diseases (DMID). These are

17 Sep 2024 update: This is now the second of a 3-part newsletter series! See also part 1 (“#AMRSOS! GRAM report: ‘at least 1.27m deaths/year

Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list

Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the quiet safety net of modern